购物车
- 全部删除
- 您的购物车当前为空
Sozinibercept (OPT 302; VGX-300) 是VEGFR-3的可溶性形式,能有效抑制血管生成原因子VEGF-C/D 的活性,抑制血管生成和血管渗漏。Sozinibercept 对大鼠糖尿病视网膜水肿也有抑制作用。
Sozinibercept (OPT 302; VGX-300) 是VEGFR-3的可溶性形式,能有效抑制血管生成原因子VEGF-C/D 的活性,抑制血管生成和血管渗漏。Sozinibercept 对大鼠糖尿病视网膜水肿也有抑制作用。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | Sozinibercept (OPT 302; VGX-300) is a soluble form of Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) that potently inhibits the activity of Vascular Endothelial Growth Factor-C and -D (VEGF-C/D), key proangiogenic factors involved in promoting angiogenesis and vascular leakage. Additionally, Sozinibercept has been shown to inhibit diabetic retinal edema in rats [1] [2] [3]. |
CAS No. | 2568358-31-4 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容